Drug Action
Tedizolid is an oxazolidinone antibacterial, which inhibits bacterial protein synthesis.
PDF page 628
Loading InternPractice…
Drug reference
Tedizolid is an oxazolidinone antibacterial, which inhibits bacterial protein synthesis.
PDF page 628
Treatment of acute bacterial skin and skin structure infections ▶BY INTRAVENOUS INFUSION, OR BY MOUTH ▶Adult: 200 mg once daily for 6 days, patients should be switched from the intravenous to the oral route when clinically appropriate
PDF page 628
Neutropenia—limited clinical experience. patients aged 75 years and over—limited clinical experience
PDF page 628
Scottish Medicines Consortium (SMC) decisions SMC No. 1080/15 The Scottish Medicines Consortium has advised (August 2015) that tedizolid (Sivextro ®) is accepted for restricted use within NHS Scotland as an alternative oxazolidinone antibacterial for the treatment of acute bacterial skin and skin structure infections caused by Gram-positive Staphylococcus aureus (specifically methicillin-resistant Staphylococcus aureus[MRSA] isolates), on the specific advice of local microbiologists or specialists in infectious disease.
PDF page 629
→Appendix 1: tedizolid
PDF page 628
GENERAL SIDE-EFFECTS ▶Common or very common Diarrhoea. dizziness. fatigue. headache. nausea. skin reactions. vomiting ▶Uncommon Abscess. alopecia. antibiotic associated colitis . anxiety. arthralgia. bradycardia. chills. constipation. cough. dehydration. diabetic control impaired. drowsiness. dry mouth. fever. gastrointestinal discomfort . gastrointestinal disorders. haematochezia. hyperhidrosis . hyperkalaemia. increased risk of infection. irritability. limb discomfort. lymphadenopathy. muscle spasms. nasal dryness. pain. peripheral oedema. pulmonary congestion . sensation abnormal. sleep disorders. taste altered. tremor. urine odour abnormal. vasodilation. vision blurred. vitreous floater. vulvovaginal pruritus SPECIFIC SIDE-EFFECTS ▶Uncommon ▶With intravenous use Infusion related reaction
PDF page 628
Manufacturer recommends effective contraception in women of childbearing potential; an additional method of contraception is advised in women taking hormonal contraceptives—effectiveness may be reduced.
PDF page 628
Manufacturer advises avoid—fetal developmental toxicity in animal studies.
PDF page 628
Manufacturer advises avoid—present in milk in animal studies.
PDF page 628
For intravenous infusion (Sivextro ®) give intermittently in Sodium Chloride 0.9%; reconstitute each 200 mg vial with 4 mL Water for Injections, then dilute reconstituted solution in 250 mL sodium chloride 0.9%; give over approx. 1 hour.
PDF page 628
There can be variation in the licensing of different medicines containing the same drug. Powder for solution for infusion ▶Sivextro (Merck Sharp & Dohme Ltd) Tedizolid phosphate 200 mg Sivextro 200mg powder for concentrate for solution for infusion vials | 6 vial P £862.00 Tablet ▶Sivextro (Merck Sharp & Dohme Ltd) Tedizolid phosphate 200 mg Sivextro 200mg tablets | 6 tablet P £862.00
PDF page 629
Optic neuropathy Although neuropathy (peripheral and optic) has not been reported in patients treated with tedizolid, manufacturer advises patients and carers are warned to report symptoms of visual impairment (including blurred vision, visual field defect, changes in visual acuity and colour vision) immediately; patients should be evaluated promptly, and referred to an ophthalmologist if necessary. Missed doses Manufacturer advises that if a dose is more than 16 hours late, the missed dose should not be taken and the next dose should be taken at the normal time. Driving and skilled tasks Patients and carers should be counselled on the effects on driving and skilled tasks— increased risk of dizziness and fatigue.
PDF pages 628, 629
200 mg once daily for 6 days, patients should be
First-line fragment. Read the complete Indications and Dose section above.
PDF page 628